Zhou Tongqing, Lynch Rebecca M, Chen Lei, Acharya Priyamvada, Wu Xueling, Doria-Rose Nicole A, Joyce M Gordon, Lingwood Daniel, Soto Cinque, Bailer Robert T, Ernandes Michael J, Kong Rui, Longo Nancy S, Louder Mark K, McKee Krisha, O'Dell Sijy, Schmidt Stephen D, Tran Lillian, Yang Zhongjia, Druz Aliaksandr, Luongo Timothy S, Moquin Stephanie, Srivatsan Sanjay, Yang Yongping, Zhang Baoshan, Zheng Anqi, Pancera Marie, Kirys Tatsiana, Georgiev Ivelin S, Gindin Tatyana, Peng Hung-Pin, Yang An-Suei, Mullikin James C, Gray Matthew D, Stamatatos Leonidas, Burton Dennis R, Koff Wayne C, Cohen Myron S, Haynes Barton F, Casazza Joseph P, Connors Mark, Corti Davide, Lanzavecchia Antonio, Sattentau Quentin J, Weiss Robin A, West Anthony P, Bjorkman Pamela J, Scheid Johannes F, Nussenzweig Michel C, Shapiro Lawrence, Mascola John R, Kwong Peter D
Vaccine Research Center, National Institute of Allergy and Infectious Diseases and National Institutes of Health, Bethesda, MD 20892, USA.
Department of Biochemistry & Molecular Biophysics and Department of Systems Biology, Columbia University, New York, NY 10032, USA.
Cell. 2015 Jun 4;161(6):1280-92. doi: 10.1016/j.cell.2015.05.007. Epub 2015 May 21.
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reactive antibodies, several of which neutralize over 90% of HIV-1 strains. To understand how antibodies achieve such neutralization, we isolated CD4-binding-site (CD4bs) antibodies and analyzed 16 co-crystal structures -8 determined here- of CD4bs antibodies from 14 donors. The 16 antibodies segregated by recognition mode and developmental ontogeny into two types: CDR H3-dominated and VH-gene-restricted. Both could achieve greater than 80% neutralization breadth, and both could develop in the same donor. Although paratope chemistries differed, all 16 gp120-CD4bs antibody complexes showed geometric similarity, with antibody-neutralization breadth correlating with antibody-angle of approach relative to the most effective antibody of each type. The repertoire for effective recognition of the CD4 supersite thus comprises antibodies with distinct paratopes arrayed about two optimal geometric orientations, one achieved by CDR H3 ontogenies and the other achieved by VH-gene-restricted ontogenies.
HIV-1糖蛋白120(gp120)上与CD4受体结合的位点可被广泛反应性抗体识别,其中几种抗体可中和超过90%的HIV-1毒株。为了解抗体如何实现这种中和作用,我们分离出了CD4结合位点(CD4bs)抗体,并分析了来自14名供体的CD4bs抗体的16个共晶体结构——本文测定了其中8个。这16种抗体根据识别模式和发育个体发生分为两种类型:互补决定区H3(CDR H3)主导型和重链可变区(VH)基因受限型。两者都能实现大于80%的中和广度,且都可在同一供体内产生。尽管抗原结合部位的化学性质不同,但所有16种gp120-CD4bs抗体复合物都表现出几何相似性,抗体中和广度与相对于每种类型最有效的抗体的接近角度相关。因此,有效识别CD4超位点的抗体库包括具有不同抗原结合部位的抗体,这些抗原结合部位围绕两种最佳几何取向排列,一种由CDR H3个体发生实现,另一种由VH基因受限个体发生实现。